skip to main content
Global Search Configuration

Refine Results

Clear All

Specialism

Show More

Resources

Show More

Products

Show More

Show More

40 Total results for product and free and sample content found

In Vivo

From US To EU: Young Biotechs Going It Alone

By Jo Shorthouse 14 Nov 2022

Analysis

Europe’s patchwork of reimbursement agencies make it a daunting place for a small US biotech to do business. Traditionally large pharma partners or CMSOs have provided an experienced hand to hold, but as a new wave of gene therapies and orphan drugs get the EMA green light, smaller drug developers are applying innovation to commercialization and choosing to go solo.

Topic Market Access Rare Diseases Strategy

Scrip

Scrip Asks...What Does 2020 Hold For Biopharma? Part 1: Therapeutic Advances

By Eleanor Malone 20 Oct 2022

Scrip_Asks_What_Does_2020_Hold_1

Advances in multiple scientific areas will mature into novel therapeutics, often tailored for the individual patient and increasingly curative, making biopharma an exciting place to be in 2020.

Topic Innovation Market Intelligence Research & Development

Biomedtracker, Scrip

39th Annual J.P. Morgan Healthcare Conference 2021

28 Jan 2021

39th Annual J.P. Morgan Healthcare Conference 2021

Keep up with events as they unfold at the 39th Annual J.P. Morgan Annual Healthcare Conference on January 11-14, 2021. Pharma Intelligence and Insights journalists will bring you real time reporting, highlighting important events and key takeaways from every day of the largest and most informative healthcare investment symposium in the industry.

Scrip

Health Sector On High Alert As Wuhan Coronavirus Spreads

By Brian Yang 27 Nov 2020

Health_Sector_On_High_Alert

The latest figures from China's National Health Commission show infections of the new Wuhan coronavirus are continuing to pile up, spreading to more cities in the country and abroad as travel for the Lunar New Year festival goes into high gear. Meanwhile, the Chinese government maintains that the situation is “preventable and controllable.”

Topic China Infectious Diseases Policy & Regulation Coronavirus

Medtech Insight

Compliance Corner: The 10 Best – And 10 Worst – Things You Can Do When FDA Inspects Your Firm (Part 1)

By Shawn M. Schmitt 27 Nov 2020

Compliance_Corner_Part_1

A panel of longtime industry experts offer manufacturers a list of things they should and shouldn’t do when an investigator from the US agency knocks on their facility door. In this first installment of a 10-part series, a procedure for hosting inspections is addressed.

Topic Compliance FDA

Medtech Insight

CES 2020: Panel Discusses Health Care In 2040 – Empowered Consumer, Digital Transformation, Data Sharing, Open Source

By Marion Webb 27 Nov 2020

CES_2020_Panel_1

An expert panel at CES 2020 discussed Deloitte's vision for health care in 2040, with the empowered consumer managing their own health, enabled by a new ecosystem of secure, open access to data and "nudges" to change behaviors. Consulting firm Deloitte foresees outside disruptors dismantling the traditional health-care system, but panelists from Johnson & Johnson and Anthem flexed their muscles.

Topic Business Strategies Digital Health

Generics Bulletin

California Plans To Create Own Generics Label

By Aidan Fry 27 Nov 2020

California_Plans_To_Create_Own_Generics_Label

California’s 2020-2021 fiscal budget includes plans to work with manufacturers to establish the state’s own generics label. But industry is sceptical that the initiative will deliver the savings that the US state hopes for.

Topic Legislation Policy & Regulation

Generics Bulletin

Biocon Biologics Gets True North Investment

By Anju Ghangurde 27 Nov 2020

Biocon_Biologics_Gets_True_North_Investment

Private equity group True North continues to back the Biocon group and is picking up a minority stake in Biocon Biologics in a deal that values the subsidiary at $3bn. Separately, another subsidiary, Biocon Biosphere, has also been set up as part of efforts to unlock the full potential of the business.

Topic Deals Strategy

Pink Sheet

A Visual Guide To US FDA's Evolutionary Decade In Review

By Brenda Sandburg 27 Nov 2020

FDAs_Evolutionary_Decade_In_Review

An interactive timeline shows the news of the past decade and the evolution of US FDA policies. Click on each year for a full list of events and see the accompanying article.

Topic FDA Policy & Regulation

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.

Contact us for product technical and account support.

  • US Toll-Free   : +1 888 670 8900 
  • US Toll             : +1 212-600-3520
  • UK & Europe : +44 (0) 208 052 0700

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: